SOMATROGON

somatrogon 24 mg/1.2 mL injection, 1.2 mL pen device

SOMATROGON (13130C)

somatrogon 24 mg/1.2 mL injection, 1.2 mL pen device
13130C
Body System:
Manner of administration:Injection
S100 Growth Hormone Programme
Authority Required

Restriction

Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment

Restriction

Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Change of drug

Restriction

Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment as a reclassified patient

Restriction

Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

Restriction

Indication: Short stature and slow growth
Treatment phase: Continuing treatment

Restriction

Indication: Short stature and slow growth
Treatment phase: Change of drug

Restriction

Indication: Short stature and slow growth
Treatment phase: Continuing treatment as a reclassified patient

Restriction

Indication: Short stature and slow growth
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $383.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Ngenla